“Silybum marianum” – properties and application in medicine – a review
DOI:
https://doi.org/10.15584/ejcem.2022.3.3Keywords:
milk thistle, silybin, silymarinAbstract
Introduction and aim. The subject of this article is milk thistle – a plant belonging to the Asteraceae family. Due to its properties, it has a beneficial effect on the functioning of important organs and systems of the human body. The aim of this paper was to review information on milk thistle, its use in medicine and the description of some of the chemical compounds due to which it owes its healing properties.
Material and methods. The article is a review of the publicly available literature on milk thistle, the chemical composition of its compounds and its use in medicine.
Analysis of the literature. Current information about Silybum marianum is presented.
Conclusion. Milk thistle is a valuable medicinal plant due to the presence of numerous antioxidant and anti-inflammatory compounds. The benefits of supplementation with ingredients derived from milk thistle, their negligible interaction with other drugs and the lack of significant side effects, known so far, indicate that the plant described in the article can be a good medicine and a preventive measure against diseases affecting our society.
Downloads
References
Andrzejewska J, Skinder Z. Ostropest plamisty-uwagi o nazewnictwie, substancjach czynnych i rozwoju rośliny. Acta Sci Pol Agricultura. 2006;5(1):5‒10.
Grau J, Jung R, Münker B. Leksykon Przyrodniczy: Zioła i Owoce Leśne,Warszawa; Świat Książki; 1996:196.
Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17(18):2288‒2301.
Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017;22(2):191.
Pickova D, Ostry V, Toman J, Malir F. Presence of Mycotoxins in Milk Thistle (Silybum marianum) Food Supplements: A Review. Toxins (Basel). 2020;12(12):782.
Bahmani M, Shirzad H, Rafieian S, Rafieian-Kopaei M. Silybummarianum: Beyond Hepatoprotection. Evid Based Complement Alternat Med. 2015;20(4):292‒301.
Nurzyńska-Wierdak R, Dyduch J, Sawicka A, Łabuda H, Buczkowska H. Ostropest plamisty (Silybummarianum [L.] Gaertn.) – fitochemia i efekty terapeutyczne. Ann Hortic. 2018;28(4):15‒32.
Verdura S, Cuyàs E, Ruiz-Torres V, et al. Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals (Basel). 2021;14(6):559.
European Scientific Cooperative on Phytotherapy. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd editionsupplement. New York, NY: Thieme; 2009:222‒248.
Salmi HA, Sarna S. Effects of silymarin on chemical, functional, and morphological alterations of the liver: a double-blind controlled study. Scand J Gastroenterol. 1982;17:517–521.
Gufford BT, Graf TN, Paguigan ND, Oberlies NH, Paine MF. Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides. Drug Metab Dispos. 2015;43(11):1734‒1743.
Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem. 2003;1(10):1684‒1689.
Kren V, Ulrichová J, Kosina P, et al. Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metab Dispos. 2000;28(12):1513‒1517.
Han YH, Lou HX, Ren DM, Sun LR, Ma B, Ji M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. J Pharm Biomed Anal. 2004;34(5):1071‒1078.
Jančová P, Siller M, Anzenbacherová E, Křen V, Anzenbacher P, Simánek V. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases. Xenobiotica. 2011;41(9):743‒751.
Křen V, Marhol P, Purchartová K, Gabrielová E, Modrianský M. Biotransformation of silybin and its congeners. Curr Drug Metab. 2013;14(10):1009‒1021.
Gillessen A, Schmidt HH. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther. 2020;37(4):1279‒1301.
Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules. 2017;22(11):1942.
Xie Y, Zhang D, Zhang J, Yuan J. Metabolism, Transport and Drug-Drug Interactions of Silymarin. Molecules. 2019;24(20):3693.
Achufusi TGO, Patel RK. Milk Thistle. Treasure Island (FL): StatPearls Publishing; 2021.
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035‒2063.
Alhidary IA, Rehman Z, Khan RU, Tahir M. Anti-aflatoxin activities of milk thistle (Silybum marianum) in broiler. Worlds Poult Sci J. 2017;73:559–566.
Zaker-Esteghamati H, Seidavi AR, Bouyeh M. A review on the effect of Silybum marianum and its derivatives on broilers under healthy and aflatoxicosis conditions: part 1: performance, carcass and meat characteristics, and intestinal microflora. Worlds Poult Sci J. 2020;76(2):318‒327.
Khazaei R, Seidavi A, Bouyeh M. A review on the mechanisms of the effect of silymarin in milk thistle (Silybum marianum) on some laboratory animals. Vet Med Sci. 2022;8(1):289‒301.
Zaker-Esteghamati H, Seidavi AR, Bouyeh M. The effects of Cynara scolymus and Silybum marianum on growth, carcass and organ characteristics, immunity, blood constitutes, liver enzymes, jejunum morphology, and fatty acid profile of breast meat in broilers. Food Sci Nutr. 2021;9(12):6692‒6706.
Opyd PM, Jurgoński A. Intestinal, liver and lipid disorders in genetically obese rats are more efficiently reduced by dietary milk thistle seeds than their oil. Sci Rep. 2021;11(1):20895.
Nassuato G, Iemmolo RM, Strazzabosco M. Effect of silibinin on biliary lipid composition experimental and clinical study. J Hepatol. 1992;12:290–295.
Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applocations of Silybum marianum in oncology.Integr Cancer Ther. 2007;6(2):158–165.
Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. Silymarin, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011;14(4):308–317.
Bethesda MD. Drugs and Lactation Database (LactMed) National Library of Medicine (US); 2006. https://www.ncbi.nlm.nih.gov/books/NBK501922/
Sagar SM. Future directions for research on Silybum marianum for cancer patients. Integr Cancer Ther. 2007;6(2):166‒173.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
